Back

Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy

2 September 2024 (11:05 - 11:15)
Organised by: Logo
Congress Presentation Part of: Risk stratification for midterm outcome after acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor David Erlinge

Skane University Hospital, Lund (Sweden)

5 More presentations in this session

Presentation thumbnail
Effects of restrictive vs liberal transfusion strategies on mortality in patients with acute myocardial infarction and anemia: The 6-month follow up primary results of the MINT trial
Professor T. Simon (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Safety of beta-blocker discontinuation in patients after acute coronary syndromes and preserved left ventricular ejection fraction: long-term clinical outcomes from the SPUM-ACS cohort
Doctor N. Johner (Bordeaux, FR)
Abstract Slides Video
Presentation thumbnail
Albumin creatinine index added to the grace score increases its discriminative capacity for mortality at 12 years of follow-up in patients with acute coronary syndrome
Doctor C. Higa (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Microcirculatory resistance after primary percutaneous coronary intervention predicts residual myocardial damage: a post hoc analysis from the CLEVER-ACS trial
Doctor A. Candreva (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Impact of baseline thrombocytopenia on outcomes in hospitalizations for acute coronary syndrome and non-elective percutaneous coronary intervention: meta-analysis
Doctor S. Senapati (El Paso, US)
Abstract Slides

Access the full session

Session thumbnail
Risk stratification for midterm outcome after acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 11:05 CET
You may be interested in
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
DAPA-MI – rationale and innovative design for a registry-based randomised clinical trial
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources